Virax Biolabs Group Ltd (VRAX)
1.94
+0.01
(+0.52%)
USD |
NASDAQ |
Sep 27, 16:00
1.94
0.00 (0.00%)
After-Hours: 20:00
Virax Biolabs Group Shareholders Equity (Quarterly): 5.367M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.367M |
| September 30, 2023 | 6.333M |
| September 30, 2023 | 6.333M |
| March 31, 2023 | 9.126M |
| September 30, 2022 | 4.393M |
| Date | Value |
|---|---|
| September 30, 2022 | 4.393M |
| March 31, 2022 | -0.9746M |
| September 30, 2021 | -0.7989M |
| September 30, 2021 | -0.7989M |
| March 31, 2021 | -0.6507M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-0.9746M
Minimum
Mar 2022
9.126M
Maximum
Mar 2023
3.272M
Average
4.393M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 96.27M |
| Biodexa Pharmaceuticals PLC | 11.04M |
| Verona Pharma PLC | 168.27M |
| NuCana PLC | 4.806M |
| Autolus Therapeutics PLC | 527.84M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 5.484M |
| Total Liabilities (Quarterly) | 0.3452M |
| Current Ratio | 25.94 |
| Net Debt Paydown Yield | 7.04% |